文献速递流行病学与生物统计临床试验与 GCP

临床试验中获益-风险评估的统计方法

A Statistical Method for Benefit-Risk Assessment in Clinical Trials.
PubMed 文献 · Stat Med · 2025-01-01

本文基于FDA近期关于获益-风险评估(BRA)的指南,统计开发了一种同时考虑安全性和有效性指标的置信椭圆方法,并引入净获益指数(NBI)、相对获益指数(RBI)和成功率指数(SRI)三个新指标。通过广泛模拟,将置信椭圆方法与全局获益-风险(GBR)评估、多标准决策分析(MCDA)和随机多标准可接受性分析(SMAA)等现有BRA技术进行比较,结果显示置信椭圆方法稳健,尤其在大样本量时,且随样本量增加敏感性降低,反映稳定性增强。本文还以一项比较新药联合放化疗与安慰剂治疗局部晚期头颈部鳞状细胞癌的假设II期临床试验说明其实际应用。

要点

  • 提出置信椭圆方法,同时考虑安全性和有效性指标,并提供可视化和定量工具。
  • 引入净获益指数、相对获益指数和成功率指数三个新指标,全面评估治疗表现。
  • 模拟显示置信椭圆方法稳健,尤其在大样本量时,且随样本量增加敏感性降低。

核心结论

  • 置信椭圆方法是稳健、适应性强且可解释的获益-风险评估工具,为现代临床试验和监管决策提供有价值的可视化和定量见解。

研究设计与样本

  • 统计方法开发研究,基于FDA关于获益-风险评估的指南,提出置信椭圆方法并引入三个新指标。
  • 通过广泛模拟比较置信椭圆方法与GBR、MCDA和SMAA等现有BRA技术。
  • 以一项假设的II期临床试验为例说明实际应用,该试验比较新药联合放化疗与安慰剂治疗局部晚期头颈部鳞状细胞癌。

主要发现

  • 模拟结果显示置信椭圆方法稳健,尤其在大样本量时。
  • 置信椭圆方法随样本量增加敏感性降低,反映稳定性增强。
  • 在假设的II期临床试验中,置信椭圆方法成功提供了细致的获益-风险评估,包括对不良事件的未加权和加权分析。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, benefit-risk assessment (BRA) has become a crucial tool in guiding regulatory decisions regarding the safety and efficacy of investigational treatments. Following the FDA's recent guidance on the BRA, we statistically develop a confidence ellipse approach that considers both safety and efficacy indices. This method addresses limitations in existing BRA frameworks by providing a visual and quantitative tool that accounts for uncertainties and heterogeneities in clinical trial data. We introduce three novel indices: the Net Benefit Index (NBI), Relative Benefit Index (RBI), and Success Rate Index (SRI), offering a comprehensive assessment of treatment performance. Through extensive simulations, we compared the confidence ellipse method with established BRA techniques such as global benefit-risk (GBR) assessment (GBR), multi-criteria decision analysis (MCDA), and stochastic multi-criteria acceptability analysis (SMAA). Our results showed the confidence ellipse method's robustness, particularly with larger sample sizes, and demonstrated decreasing sensitivity as sample sizes increased, reflecting enhanced stability. To illustrate the method's practical application, we present a hypothetical Phase 2 clinical trial comparing a new drug combined with chemoradiotherapy against placebo for locally advanced squamous cell carcinoma of the head and neck. The confidence ellipse approach successfully provided a nuanced benefit-risk assessment, incorporating both unweighted and weighted analyses for adverse events. Overall, the confidence ellipse method is a robust, adaptable, and interpretable tool for benefit-risk assessment, offering valuable visual and quantitative insights for decision-making in modern clinical trials and regulatory processes.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Chow SC. A Statistical Method for Benefit-Risk Assessment in Clinical Trials. Stat Med. 2025. PMID: 40772718. doi:10.1002/sim.70208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。